Investors
Worldwide Challenge Investment Opportunity
Investing in CogniTherapeutics offers an opportunity to support innovative cognitive health solutions while potentially achieving strong returns. Compliant with the EII scheme that allows 87.5% of the investment made in 2024 to be written off against taxable income for 2024, this investment combines financial incentives with a mission-driven focus. Backed by experienced founders, patented products, and advancements in AI and machine learning, CogniTherapeutics is positioned for growth in a market catering to diverse demographics, from children to individuals in rehabilitation. This opportunity is ideal for investors looking to align profit with impactful, health-focused innovation.